fashion -WSS

fashion

author：leisure time 2025-09-30 00:38:00 - browse：99182

Christine Kao/STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves. So when new market developments threaten to diminish or wipe away that revenue stream, PBMs find crafty ways to keep as much of those dollars as possible — often at the expense of employers.

One such case occurred last year, when a wave of Humira biosimilars entered the market and drug companies slashed the list prices of their insulin products. CVS Caremark, the PBM owned by CVS Health that oversees the prescription drug benefits of 103 million people, told its employer clients that it anticipated “more lower-cost products (including specialty biosimilars) may become preferred products” on its lists of approved drugs for 2024, according to documents obtained by STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Having children helps parents live longer, especially after age 80

explore

WSS

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Lack of darker skin in textbooks, journals harms patients of color

Study gives hint on South Asians’ higher risk of cardiovascular disease

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

focus

fashion

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Bright Health sells Medicare Advantage business to Molina

Too many hospitalized Covid

What does generative AI mean for health care? We asked experts

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Jerome Adams on the need for new antivirals for Covid

15 die by electrocution after transformer explodes in northern India

How one medical school became remarkably diverse

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

explore

House passes resolution saying Israel isn't a 'racist or apartheid state'

Tome Biosciences co

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Doctors on social media are being harassed and cyberbullied

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Artificial intelligence use in health care faces greater scrutiny in 2024

explore

entertainment

focus

focus